Core Viewpoint - Wantai Biological Pharmacy's subsidiary, Xiamen Wantai Canghai Biotechnology Co., Ltd., has received the acceptance notice from the National Medical Products Administration for its clinical trial application of the "Recombinant Trivalent Rotavirus Subunit Vaccine (Escherichia coli)" [1] Group 1 - The vaccine is produced using genetic engineering recombinant technology with an Escherichia coli expression system [1] - The main active ingredient of the vaccine is a truncated rotavirus spike protein VP4 [1]

Core Viewpoint - Wantai Biological Pharmacy (603392.SH) has received acceptance for its clinical trial application for the "Recombinant Trivalent Rotavirus Subunit Vaccine (E. coli)" from the National Medical Products Administration, marking a significant step in the company's innovative vaccine development process [1] Group 1 - The acceptance of the clinical trial application is a crucial advancement in the company's recombinant protein vaccine development strategy based on its proprietary E. coli technology platform [1] - Successful future commercialization of this product could enhance the company's product portfolio and further improve its market competitiveness [1]

Core Viewpoint - Wanta Biotechnology (603392.SH) has received acceptance for its clinical trial application for the "Recombinant Trivalent Rotavirus Subunit Vaccine (E. coli)" from the National Medical Products Administration, marking a significant step in the company's vaccine development process [1] Group 1 - The acceptance of the clinical trial application is a crucial advancement in the company's innovative vaccine research and development [1] - This development signifies a key progress in the company's recombinant protein vaccine research strategy based on its proprietary E. coli technology platform [1] - Successful future commercialization of this product could enhance the company's product portfolio and further improve its market competitiveness [1]